SOLN5957384 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Solventum Corporation bond SOLN5957384, featuring a 5.4% coupon rate and maturing on March 1, 2029. It outlines key facts about the issuer, bond classification, interest payment schedule, and redemption information, catering to investors evaluating its potential performance.
SOLN5957404 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Solventum Corporation bond, SOLN5957404, highlighting its key characteristics. It outlines essential information such as the issuer, issue and maturity dates, face value, coupon rate, and semi-annual payment schedule. The profile also details the outstanding amount and offers insights into redemption information for the bond.
Vylor, Inc. (VYLR) Stock Price, News, Quote & History
This article provides comprehensive financial data for Vylor, Inc. (VYLR), including its stock price, historical performance, key financial metrics, and analyst ratings. As of October 2nd, Vylor Inc. closed at $67.26, with an overnight price of $67.51. The company, founded in 1802, specializes in seed and genetics within the financial services sector.
SOLN5957403 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Solventum Corporation bond SOLN5957403, outlining its key facts, coupon payments, and redemption information. It covers details like the issuer, issue date, maturity date, face value, interest rate, and upcoming coupon payout schedule. The bond has a 5.45% fixed semi-annual coupon, maturing on March 13, 2031.
SOLN5759822 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Solventum Corporation bond SOLN5759822, highlighting its key characteristics, coupon payments, and redemption information. The bond has a 5.45% coupon rate, a maturity date of February 25, 2027, and pays semi-annual interest. It also includes information on the issuer's profile and credit risk assessment.
Solventum Corporation (SOLV) stock price, news, quote and history
This article provides a comprehensive overview of Solventum Corporation (SOLV), including its current stock price, financial data, and company profile. It details the company's segments (Medsurg, Dental Solutions, Health Information Systems), key financial metrics, and analyst insights. The report also includes performance comparisons against the S&P 500 and lists valuation measures.
Solventum Corp. stock rises Friday, outperforms market
Solventum Corp. (SOLV) shares increased by 1.03% to $89.50 on Friday, outperforming the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average also saw gains, with Solventum marking its second consecutive day of increases.
Participation notification by Citigroup Inc.
Citigroup Inc. has notified Solvay S.A. of a transparency notification indicating that they crossed a 3% threshold of voting rights on September 21, 2026. This notification signifies a downward crossing of the lowest threshold due to the acquisition or disposal of voting securities. Solvay, a pioneering chemical company, highlights its commitment to sustainable solutions and a carbon-neutral future.
Nextpower at BNP Paribas Annual Power Up Conference: demand stays strong
Nextpower presented a cautiously optimistic outlook on the U.S. solar market at the BNP Paribas Annual Power Up Conference, acknowledging challenges like tariffs and permitting delays but emphasizing strong demand driven by data centers, AI, and manufacturing. Panelists from Nextpower, SOLV Energy, DESRI, and Sol Systems highlighted significant project backlogs and the increasing importance of battery storage, despite rising costs and policy pressures. The discussion concluded that while the industry faces near-term hurdles, long-term growth is robust due to fundamental changes in electricity demand and ongoing innovation.
Solventum (NYSE:SOLV) Forms Tight Breakout Setup as Technical Strength Builds
Solventum (NYSE:SOLV) shows a strong technical setup for a potential breakout, according to ChartMill's analysis. The healthcare company has consolidated after a strong run, exhibiting high technical and setup quality ratings. This makes it an interesting candidate for investors looking for defined entry and risk levels within an established uptrend.
Solventum Corp (KB7.MU) balance sheet – Yahoo Finance
This article provides the balance sheet data for Solventum Corp (KB7.MU) as reported on Yahoo Finance. It includes annual financial figures in thousands of USD for key metrics like total assets, liabilities, equity, and debt from 2022 to 2025. The data gives an overview of the company's financial position over these years.
How to Buy 3M Stock (MMM) in 2026
This article provides a comprehensive guide on how to buy 3M stock in 2026, detailing the company's financial performance, dividend policy, and suitability for different types of investors. It highlights 3M's diversified product portfolio, profitability, and status as a dividend-paying industrial giant, while also noting its slower growth compared to tech companies. The piece also explains how to invest in 3M through ETFs and addresses potential stock splits.
Solventum Corp. stock rises Friday, outperforms market
Solventum Corp. (SOLV) stock increased by 1.50% on Friday, closing at $88.84. This rise occurred during a mixed trading session where the S&P 500 Index saw a slight increase and the Dow Jones Industrial Average experienced a minor decline. The stock's performance ended a two-day losing streak, outperforming the broader market on this day.
Stifel reiterates Solventum stock Buy rating, $100 price target By Investing.com
Stifel has reiterated its Buy rating and $100 price target for Solventum (NYSE: SOLV) shares. The firm adjusted its financial projections for the medical technology company, raising its 2027 organic growth estimate for the MedSurg division while lowering gross margin forecasts for 2027 and 2028 due to anticipated pricing mark-ups from a supply agreement with 3M. Solventum recently surpassed Q2 earnings expectations, leading to a raised future outlook, though some gains were attributed to one-time items.
Stifel reiterates Solventum stock Buy rating, $100 price target
Stifel has reiterated its Buy rating and $100 price target for Solventum (NYSE:SOLV) shares. The firm adjusted its financial projections, raising the 2027 organic growth estimate for the MedSurg division and revising gross margin forecasts due to pricing mark-ups under a supply agreement with 3M. Solventum recently reported strong Q2 financial results, beating Wall Street expectations with adjusted earnings of $2.55 per share and revenue of $2.2 billion, leading to a raised future outlook.
Analysts Offer Insights on Healthcare Companies: McKesson (MCK), AgomAb Therapeutics NV ADR (AGMB) and Solventum Corporation (SOLV)
This article highlights bullish analyst sentiments for three healthcare companies: McKesson (MCK), AgomAb Therapeutics NV ADR (AGMB), and Solventum Corporation (SOLV). Analysts from Bank of America Securities and Piper Sandler have maintained Buy ratings, with price targets indicating significant upside potential for AgomAb Therapeutics NV ADR and moderate upside for McKesson and Solventum Corporation. The article details the specific analyst ratings, price targets, and their average success rates according to TipRanks.
Solventum Corp. stock falls Thursday, underperforms market
Shares of Solventum Corp. (SOLV) fell 1.46% on Thursday, closing at $87.53. This decline occurred on a day when the broader market performed positively, with the S&P 500 Index (SPX) and the Dow Jones Industrial Average (DJIA) both seeing gains. This marks the second consecutive day of losses for Solventum Corp. stock.
Here's Why You Should Hold Solventum Stock in Your Portfolio for Now
Solventum Corporation (SOLV) is positioned for growth due to strong demand across its business segments, innovation investments, and a solid second-quarter 2026 performance with earnings surpassing estimates. The company's "Transform for the Future" program aims for significant cost savings, and its strategic growth drivers, including new product launches and segment-specific expansion, are expected to fuel future growth. However, potential raw material cost increases from a 3M supply agreement remain a concern.
Solventum Corp Lobbyists, 2026
This article from OpenSecrets details Solventum Corp's lobbying activities in 2026, including total spending, hired firms, and individual lobbyists. It highlights that Solventum Corp spent $550,000 on lobbying, employing 14 lobbyists, with 8 of them having a "revolving door" background, meaning they previously worked in the federal government. The data also breaks down lobbyists by firm and their prior government experience.
Align Technology (ALGN) Following Invisalign Expansion, Fair Value Still Sits Higher
Align Technology (ALGN) is heading into its 2026 Global Healthcare Conference with its stock currently trading at $147.0, a significant drop from its estimated fair value of $209.07, suggesting it is 30% undervalued. This valuation is based on the continued expansion of Invisalign, increasing adoption by general practitioner dentists, and anticipated double-digit earnings growth, despite recent short-term share price pressure and an EU antitrust investigation. Investors are encouraged to consider these factors alongside potential risks to make informed decisions.
Check Point Software Announces Appointment of Yoram Tietz to its Board of Directors
Check Point Software Technologies Ltd. has announced the appointment of Yoram Tietz to its Board of Directors. Mr. Tietz, a Senior Advisor at General Atlantic and former Managing Partner at Ernst & Young Israel, brings over three decades of experience mentoring technology companies and founders. His expertise is expected to significantly contribute to Check Point's strategic direction during a period of rapid technological change in cybersecurity.
Align Technology (ALGN) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed
Align Technology's stock has significantly declined over five years, yet current earnings multiples suggest it is undervalued. The company trades at a P/E ratio of 25.9x, close to its sector average, while its fair P/E is estimated at 30.0x, indicating a potential discount. Despite this, broader valuation metrics present a mixed picture, suggesting investor caution regarding future demand and profitability.
Solventum Corp. stock falls Tuesday, underperforms market
Shares of Solventum Corp. (SOLV) fell 1.72% on Tuesday, closing at $90.11. This decline occurred during a broader market downturn, with the S&P 500 Index and Dow Jones Industrial Average also experiencing losses. This marks the second consecutive day of losses for the stock.
Solventum (SOLV) Up 11.4% Since Last Earnings Report: Can It Continue?
Solventum (SOLV) shares have risen 11.4% since its last earnings report, outperforming the S&P 500. The company reported strong Q2 2026 results, beating revenue and EPS estimates, driven by organic sales growth and advance orders. Solventum has also raised its 2026 outlook, although analyst estimates have shown a downward trend since the earnings release.
Hanson Bryan C Reports 185,515 Shares in Solventum After Exercising Options and Forfeiture
Hanson Bryan C, CEO of Solventum Corp. (NYSE:SOLV), exercised options for 67,261 shares and forfeited 26,468 shares at $90.95 each. These transactions resulted in his reported ownership of Solventum shares decreasing to 185,515. Prior to the forfeiture, his reported ownership after exercising derivative securities was 211,983 shares, with no derivative securities remaining.
Solventum CEO Bryan Hanson Completes RSU Settlement and Share Withholding on September 1, 2026
Solventum Corp CEO Bryan C. Hanson settled 67,261 fully vested restricted stock units (RSUs) and had 26,468 shares withheld for tax purposes on September 1, 2026. The shares withheld were valued at $90.95 each. Following these transactions, Hanson's direct beneficial ownership in Solventum common stock stands at 185,515 shares.
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
Solventum (NYSE: SOLV) announced its participation in the 2026 Wells Fargo Healthcare Conference. Management will hold a fireside chat on Wednesday, September 9, 2026, at approximately 10:15 a.m. EDT in Boston, MA. A replay of the event will be available on the company's investor relations website.
Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
Solventum (NYSE: SOLV) announced that its management will participate in a fireside chat at the Wells Fargo Healthcare Conference on September 9, 2026, in Boston, MA. The event will begin at approximately 10:15 a.m. EDT. A live and archived replay of the chat will be available on the company's investor relations website.
A Boston fireside chat will be available live, then replayed online
Solventum (NYSE: SOLV) announced its participation in the 2026 Wells Fargo Healthcare Conference, with a fireside chat scheduled for September 9, 2026, at approximately 10:15 a.m. EDT in Boston. A live webcast and an archived replay of the session will be accessible on the company’s investor relations website. The news was released on September 2, 2026, and the stock (SOLV) closed 0.60% above its previous close on September 3.
Solventum Corp. stock rises Wednesday, outperforms market
Solventum Corp. (SOLV) stock rose 1.04% to $91.90 on Wednesday, outperforming the broader market. This rise ended a two-day losing streak for the company's shares. The S&P 500 Index and the Dow Jones Industrial Average also saw gains during the trading session.
Solventum Corp stock hits 52-week high at 93.6 USD By Investing.com
Solventum Corp (SOLV) stock recently hit a 52-week high of $93.60, currently trading at $93.99. This milestone reflects a 26.79% increase over the past year, driven by strong market conditions and strategic initiatives. Despite a P/E ratio of 9.3, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value.
Solventum Corp stock hits 52-week high at 93.6 USD
Solventum Corp's stock has reached a 52-week high of $93.60, currently trading at $93.99, marking a 26.79% increase over the past year. Despite its $15.5 billion market cap and a P/E ratio of 9.3, InvestingPro analysis suggests the stock might be overvalued relative to its Fair Value. This comes after the company reported strong second-quarter earnings, surpassing Wall Street expectations with adjusted earnings of $2.55 per share and increased revenue of $2.2 billion, leading to a raised future outlook.
Solventum Corp stock hits 52-week high at 93.6 USD By Investing.com
Solventum Corp's stock has reached a 52-week high of $93.60, with a current trading price of $93.99. This represents a 26.79% increase over the past year, driven by strong market conditions and strategic initiatives, despite InvestingPro analysis suggesting it might be overvalued. The company recently reported second-quarter earnings that surpassed Wall Street expectations, with adjusted earnings of $2.55 per share and revenue of $2.2 billion, leading to a raised outlook.
Solventum Corp stock hits 52-week high at 93.6 USD
Solventum Corp's stock has reached a new 52-week high of $93.60, currently trading at $93.99, marking a 26.79% increase over the past year. This milestone follows a strong second quarter where the company exceeded earnings expectations, reporting $2.55 per share against a forecast of $1.51, and raised its future outlook. Despite being potentially overvalued according to InvestingPro, the performance reflects robust market conditions and strategic success.
Clear Aligners Market
The global clear aligners market is projected to grow from USD 6.09 billion in 2026 to USD 11.04 billion by 2031, exhibiting a CAGR of 12.6%. This growth is driven by increasing preference for aesthetic orthodontic treatments, advancements in digital dentistry, and expanding access to clear aligner therapy. Key market players include Align Technology, AngelAlign Technology, Envista Holdings, and Straumann Group.
Panoramic Capital LLC Acquires New Position in First Solar, Inc. $FSLR
Panoramic Capital LLC has acquired a new position in First Solar, Inc. (FSLR), purchasing 32,500 shares valued at approximately $7.7 million, making it their 12th largest holding. Despite institutional ownership of 92.08% and positive analyst ratings, insiders have sold shares recently, and the stock faces mixed policy impacts, including limited benefits from new foreign-inverter restrictions and ongoing investor investigations. First Solar reported strong quarterly EPS but a slight year-over-year revenue decline.
Biotech Stocks At 52-Week Highs - VOGX, PHVS, SOLV, IKT, HTFL
Several biotech stocks, including Vogenx Inc. (VOGX), Pharvaris N.V. (PHVS), Solventum Corporation (SOLV), Inhibikase Therapeutics Inc. (IKT), and HeartFlow Inc. (HTFL), reached 52-week highs on August 24, 2026. These gains were primarily driven by positive clinical trial results, upcoming conference participation, or strong financial performance and strategic realignments. The article details the specific advancements and financial updates for each company contributing to their stock performance.
Solventum Corp. stock rises Monday, outperforms market
Solventum Corp. (SOLV) stock increased by 1.88% to $91.25 on Monday, outperforming the broader market during a mixed trading session. The Dow Jones Industrial Average rose, while the S&P 500 Index declined. This marks the fifth consecutive day of gains for Solventum Corp. stock.
Solventum Corp stock hits 52-week high at 90.05 USD
Solventum Corp's stock has reached a new 52-week high at $90.05, reflecting strong investor confidence and a 23.12% increase over the past year. The company's recent second-quarter earnings surpassed Wall Street expectations, driven by strong organic growth and a tariff refund, leading to an adjusted earnings of $2.55 per share against a forecast of $1.51. Solventum has also raised its future outlook, indicating confidence in continued growth.
Solventum Corp stock hits 52-week high at 90.05 USD
Solventum Corp's stock has reached a 52-week high of $90.05, driven by strong investor confidence and positive market performance, including a 23.12% increase over the past year. The company recently reported second-quarter earnings that surpassed Wall Street expectations, with adjusted earnings of $2.55 per share and revenue of $2.2 billion, leading to a raised outlook for future growth. InvestingPro analysis suggests the stock is fairly valued with a market capitalization of $15.25 billion and a P/E ratio of 9.3.
Why Did Align Technology (ALGN) Move Today?
Align Technology (ALGN) has seen recent share price movements, closing at $162.55, with a 1-day gain of 2.27% but a 7-day decline of 10.35%. Despite recent volatility, the company is considered 22.3% undervalued by analysts, with a fair value estimate of $209.07, driven by the expansion of Invisalign indications and increased adoption by dentists. However, key risks include competition from lower-priced clear aligner products and an ongoing EU antitrust investigation.
Solv Energy: American securities, 10% owner, sells $220.5m stock
American Securities LLC, a 10% owner of SOLV Energy, Inc. (NASDAQ:MWH), sold approximately $220.5 million worth of Class A common stock on August 19, 2026. Despite a recent 11% stock decline, InvestingPro analysis indicates the company remains undervalued. Concurrently, affiliated entities acquired shares through an exchange of SOLV Energy Holdings LLC Interests.
Solventum Corp. stock rises Friday, outperforms market
Solventum Corp. (SOLV) shares increased by 1.08% on Friday, closing at $89.57. This performance outpaced the broader market, with the S&P 500 Index rising 0.43% and the Dow Jones Industrial Average gaining 0.98%. This marks the fourth consecutive day of gains for Solventum Corp.
Solventum (SOLV) discloses insider share dealings
Solventum Corp (SOLV) reported an insider share transaction involving Neil Craig Zieselman, SVP, Controller & CAO. The transaction details the grant/award of 6,911 Restricted Stock Units (RSUs) with a vesting schedule over three tranches from August 2027 to August 2029. This Form 4 filing indicates a neutral impact and sentiment regarding the transaction.
R1 to acquire Humata Health for AI-driven prior authorizations
R1 RCM is set to acquire Humata Health, a prior-authorization technology provider, to enhance its AI-powered Phare Operating System. This acquisition aims to accelerate the prior authorization process using agentic AI, moving R1 closer to an autonomous revenue cycle platform and addressing inefficiencies and delays in healthcare. The deal is expected to close by the end of the third quarter of 2026, with Humata Health integrating into R1's AI development team.
Solventum Corp. stock falls Monday, underperforms market
Solventum Corp. (SOLV) shares fell 2.00% on Monday, closing at $86.82, and underperformed the broader market, which also saw declines. This drop ended a three-day winning streak for the stock. The S&P 500 Index and Dow Jones Industrial Average both experienced losses during the trading session.
Diamond Hill Capital Management LLC Investment Advisor Buys Shares of 1,945,121 Solventum Corporation $SOLV
Diamond Hill Capital Management LLC Investment Advisor recently acquired a new stake of 1,945,121 shares in Solventum Corporation (NYSE:SOLV) during the second quarter, valued at approximately $150 million. This investment represents 1.2% of Diamond Hill's portfolio, making it their 28th largest position. Other institutional investors have also adjusted their holdings in Solventum, and analysts currently have a "Hold" rating on the stock with an average price target of $91.64.
Assenagon Asset Management S.A. Trims Position in Solventum Corporation $SOLV
Assenagon Asset Management S.A. significantly reduced its stake in Solventum Corporation by 99.2% in Q2, selling 359,522 shares and retaining 2,882 shares. This reduction occurred despite Solventum reporting stronger-than-expected quarterly earnings and maintaining its fiscal 2026 EPS guidance. While the stock's performance has been strong, opening near its 52-week high, analyst sentiment remains mixed, resulting in a consensus "Hold" rating.
M3 Wealth Management LLC Buys Shares of 32,320 Southern Company (The) $SO
M3 Wealth Management LLC has acquired 32,320 shares of Southern Company (NYSE:SO), valued at approximately $3.1 million, making it 2% of their investment portfolio. Southern Company has a strong institutional ownership of 64.1% and recently reported Q2 EPS of $1.13, exceeding expectations, and declared a quarterly dividend of $0.76. Analysts generally maintain a "Hold" rating for the stock with an average price target of $100.09.
How (SOLV) Movements Inform Risk Allocation Models
This article analyzes Solventum Corporation (NASDAQ: SOLV) using AI models to provide trading strategies and risk allocation insights. Key findings indicate a breakout underway with compelling upside potential due to strong near and mid-term sentiment, and no resistance levels above the current price. Three distinct trading strategies are presented for different risk profiles.
